Takeda Pharmaceutical : Announces New Assignments of Directors
June 24, 2020 at 04:48 am
Share
Osaka, Japan, June 24, 2020 --- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ('Takeda') today announced new assignment of Directors. The details are as follows;
New assignment of Non-Audit and Supervisory Committee Directors effective June 24, 2020;
Name
Category
Role
Christophe Weber
Internal
Existing
Representative Director,
President & Chief Executive Officer
Masato Iwasaki
Internal
Existing
Director, President, Japan Pharma Business Unit
Andrew Plump
Internal
Existing
Director, President, Research & Development
Constantine Saroukos
Internal
Existing
Director, Chief Financial Officer
Masahiro Sakane
External
Existing
External Director, Chair of the Board Meeting
Olivier Bohuon
External
Existing
External Director
Jean-Luc Butel
External
Existing
External Director
Ian Clark
External
Existing
External Director
Yoshiaki Fujimori
External
Existing
External Director
Steven Gillis
External
Existing
External Director
Shiro Kuniya
External
Existing
External Director
Toshiyuki Shiga
External
Existing
External Director
New assignment of Audit and Supervisory Committee Directors effective June 24, 2020;
Name
Category
Role
Yasuhiko Yamanaka
Internal
Existing
Director, Full-time Audit & Supervisory Committee member
Koji Hatsukawa
External
Existing
External Director, Chairperson of Audit & Supervisory Committee
Emiko Higashi
External
Existing
External Director, Audit & Supervisory Committee member
Michel Orsinger
External
Existing
External Director, Audit & Supervisory Committee member
New assignment of Compensation committee and Nomination committee effective June 24, 2020;
Takeda Pharmaceutical Co. Ltd. published this content on 24 June 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 June 2020 08:36:03 UTC
Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas:
- sale of drugs and consumer care products;
- services.
Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United States (49%), Europe and Canada (20.8%), Latin America (3.8%), Russia and CIS (1.8%) and other (2.1%).